---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-23-005425"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2023-04-05T23:59:59+00:00"
generated_at: "2026-06-17T05:44:29.449537+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Precigen enters amended license with Alaunos for TCR products; Alaunos pays $75K annual fee

## Summary
- Precigen grants Alaunos exclusive, worldwide, royalty-free license for T-cell receptor products targeting neoantigens and HPV.
- Alaunos also gets exclusive license for Sleeping Beauty technology for TCR products for neoantigens and shared antigens.
- Alaunos pays $75,000 annual license fee; no milestones or royalties on products.
- Alaunos loses rights to IL-12, CAR (CD-19, BCMA), and Gorilla IL-12 products; Precigen retains those.
- Precigen may develop products outside the exclusive license; Alaunos can terminate on country/program basis.

## SEC filing metadata
- accession: 0000950103-23-005425
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2023-04-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010323005425/0000950103-23-005425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010323005425/dp191956_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-23-005425
- JSON: https://secwatch.observer/filing/0000950103-23-005425.json
- Plain text: https://secwatch.observer/filing/0000950103-23-005425.txt

## Key facts
- Material Agreements
  PRECIGEN, INC. amended License Agreement with Alaunos Therapeutics valued at $75,000 (effective 2023-04-03).
  - Action: amendment
  - Agreement: license
  - Counterparty: Alaunos Therapeutics
  - Value: $75,000
  - Effective: 2023-04-03
  source text: On April 3, 2023, Precigen, Inc., (the “Company”), entered into an amended and restated exclusive license agreement (the “License Agreement”), with Alaunos Therapeutics (“Alaunos”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356090/000095010323005425/0000950103-23-005425-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.